Prescription savings platform GoodRx is collaborating with pharma giant Novo Nordisk to make Ozempic and Wegovy pens available to eligible self-paying patients using GoodRx for $499 per month at retail pharmacies nationwide.
GoodRx said the collaboration lowers the price for two of the most sought-after GLP-1 medications, making them more accessible for people with inadequate insurance coverage.
"Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them," Wendy Barnes, president and CEO of GoodRx, said in a statement.
"By partnering with Novo Nordisk, we’re taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them. It’s a powerful example of how the GoodRx platform can deliver savings at scale, bridging gaps in coverage and ensuring more people can get the care they deserve."
THE LARGER TREND
According to the CDC, the percentage of adults diagnosed with diabetes in 2024 who useD GLP-1 injectables was 26.5%.
Use increased with age among adults 18 to 34 (25.3%) and 50 to 64 (33.3%) and decreased among those 65 and older (20.8%).
Among adults with diagnosed diabetes, those who took insulin (31.3%) or oral glucose-lowering medications (28.1%) were more likely to use GLP-1 injectables compared to those who did not take those medications (24.5% and 22.2%, respectively).
In June, GoodRx launched a new subscription service for erectile dysfunction, and GoodRx Community Link, which aims to address challenges that independent community pharmacies face around reimbursement models.
According to GoodRx, Community Link leverages a cost-plus pricing model based on National Average Drug Acquisition Cost to provide predictable pricing and favorable economics.
In January, GoodRx launched GoodRx for Pets, which aims to offer a more affordable and convenient method for people to access pet medications.
With GoodRx for Pets, pet owners can obtain medications and have them delivered to their door.
In June, Novo Nordisk collaborated with WeightWatchers to offer Wegovy through NovoCare Pharmacy.
Through the partnership, WeightWatchers' telehealth program, integrated into NovoCare Pharmacy, allows new uninsured or self-paying patients to access Wegovy for a monthly fee.
Novo Nordisk said the offer helps patients "previously prescribed unapproved 'semaglutide' start on FDA-approved Wegovy."
WeightWatchers dispenses Wegovy via CenterWell Pharmacy, which handles prescription fulfillment and delivery for NovoCare Pharmacy.
